Linked Life Data

20637767

Source:http://linkedlifedata.com/resource/pubmed/id/20637767

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
39
pubmed:dateCreated
2010-9-13
pubmed:abstractText
The immunogenicity and protective efficacy in mice of intranasally (i.n.) administrated influenza subunit antigens together with lipid-based adjuvants (Eurocine) were compared to those of subcutaneous (s.c.) immunisation. Influenza hemagglutination inhibition (HAI) and ELISA IgG titers were similar in the group's vaccinated s.c. and after i.n. vaccination with adjuvants. The virus-specific IgA levels in serum were higher after vaccination i.n. with adjuvant than after s.c immunisation. Virus-specific IgA was measurable in nasal washings only after i.n vaccinations, with and without adjuvants. Thus, i.n. vaccination with the endogenous non-toxic, lipid adjuvants induced equal or stronger antibody responses as compared to s.c. immunisation with the same antigen. We further analysed the protective efficacy against virus challenge in a mouse model. A subunit antigen preparation of the A/New/Caledonia/20/99 strain was used for vaccination of NMRI mice with different combinations of adjuvants. The mice were challenged i.n. with 6.5 tissue culture infectious doses(50) of homologous virus and sacrificed 3 days later. Since the virus is not lethal in mice, the protective efficacy was measured by quantitative, real-time PCR on pulmonary tissue, obtained at autopsy. The mice treated with only adjuvant and the group of naïve mice clearly had the highest mean viral RNA copy numbers (19.200 and 11.000, respectively). All vaccinated groups had significantly lower copy numbers, especially the mice that received the L3A i.n. (-median 120; i.n. L3B-median 2.200; and non-adjuvanted s.c. vaccination-median 2.600). Our findings prompt further investigations of the effect of the formulations in ferrets, monkeys and man.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1873-2518
pubmed:author
pubmed:copyrightInfo
Copyright © 2010 Elsevier Ltd. All rights reserved.
pubmed:issnType
Electronic
pubmed:day
7
pubmed:volume
28
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
6491-7
pubmed:meshHeading
pubmed-meshheading:20637767-Adjuvants, Immunologic, pubmed-meshheading:20637767-Administration, Intranasal, pubmed-meshheading:20637767-Animals, pubmed-meshheading:20637767-Antibodies, Viral, pubmed-meshheading:20637767-Antigens, Viral, pubmed-meshheading:20637767-Female, pubmed-meshheading:20637767-Hemagglutination Inhibition Tests, pubmed-meshheading:20637767-Immunoglobulin A, pubmed-meshheading:20637767-Immunoglobulin G, pubmed-meshheading:20637767-Influenza A Virus, H1N1 Subtype, pubmed-meshheading:20637767-Influenza A Virus, H3N2 Subtype, pubmed-meshheading:20637767-Influenza Vaccines, pubmed-meshheading:20637767-Lipids, pubmed-meshheading:20637767-Lung, pubmed-meshheading:20637767-Mice, pubmed-meshheading:20637767-Orthomyxoviridae Infections, pubmed-meshheading:20637767-RNA, Viral, pubmed-meshheading:20637767-Vaccines, Subunit
pubmed:year
2010
pubmed:articleTitle
The Eurocine L3 adjuvants with subunit influenza antigens induce protective immunity in mice after intranasal vaccination.
pubmed:affiliation
Swedish Institute for Infectious Disease Control, 171 82 Solna, Sweden.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't